TLXTelix Pharmaceuticals Limited
Is it safe?
Mostly sound, with a caveat: insiders buying, but big price swings.
Insiders were net buyers (+$20K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -69% · now 13% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TLX take a bad year?
Telix Pharmaceuticals Limited carries $263M of net debt at 5.13× EBITDA: a heavy load to carry through a bad year.
Net debt · as at FY2025 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 5.13×
Net debt / EBITDA · −1.44× a year ago · the load is going up
- Cash runway
- 3.3 years
Cash runway · burning $11M a quarter at the current rate
- Annualised volatility
- 57%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtFY2025
- $405M
- Cash and short-term investments
- $142M
- Net debt
- $263M
- EBITDA, trailing twelve months
- $51M
- Operating profit, trailing twelve months
- $30M
- Debt / equity
- 0.97×
- Total debt / EBITDA
- 7.90×
- Annualised volatilitytwo years of daily moves
- 57%
- Worst drawdown on file
- −69%
- Below its 52-week high
- 13%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry